Biotech: Page
-
Getty Images
Forbion-backed biotech Progentos debuts with $65M for MS drug
Progentos says the money will go toward expanding its pipeline and pushing an experimental treatment for multiple sclerosis through "proof of concept” testing.
By Jacob Bell • May 20, 2024 -
Getty Images
BIO to restructure, lay off staff in shakeup of lobbying group
Thirty employees will leave as part of the reorganization, which the group said is meant to bring "stronger focus and greater impact" to its work.
By Ned Pagliarulo • May 20, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.
By BioPharma Dive staff -
Elizabeth Regan/BioPharma Dive
Dyne shares jump on trial data for muscle disease drugs
Updated study results for the biotech’s medicines for myotonic dystrophy Type 1 and Duchenne muscular dystrophy appeared to impress analysts and investors on Wall Street.
By Ned Pagliarulo • May 20, 2024 -
Carl Court via Getty Images
European Commission, in ‘unprecedented’ move, declines to revoke approval of PTC Duchenne drug
Rather than endorse the recommendation of the EMA, the commission called for a new review for Translarna that considers “the totality of the evidence” compiled to date.
By Ben Fidler • May 20, 2024 -
vitanovski/stock.adobe.com
Sponsored by IO BiotechTherapies designed to dismantle cancer’s escape mechanisms show promise for patients
Hear from IO Biotech CEO Dr. Mai-Britt Zocca about the potential of therapeutic vaccines to strip the defenses used by cancer cells to keep the immune system at bay.
By Mai-Britt Zocca, Ph.D., founder and chief executive officer, IO Biotech • May 20, 2024 -
Getty Images
Erasca restructures; Novartis moves to complete MorphoSys deal
The cancer biotech is laying off one-fifth of its staff and scrapping three drugs. Elsewhere, Novartis secured sufficient support for its $3 billion buyout and Bristol Myers won a new CAR-T approval.
By BioPharma Dive staff • May 17, 2024 -
Getty Images
Investors put $400M into biotech licensing obesity drugs from China
The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.
By Gwendolyn Wu • May 16, 2024 -
Permission granted by Biogen
ALS drug developmentBiogen, Ionis shelve ALS drug following study failure
While results indicated the drug works as intended, it didn’t have enough of an effect on a protein that’s become integral to many ALS research programs.
By Jacob Bell • May 16, 2024 -
Getty Images
Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate
The company will cut its workforce by half and shuffle leadership as it discontinues testing of the drug trastuzumab imbotolimod.
By Delilah Alvarado • May 15, 2024 -
Getty Images
Blackstone-backed biotech launches with up to $300M for immune drug
Uniquity Bio emerged from stealth mode ready to begin Phase 2 trials of an antibody targeting the protein TSLP in asthma and COPD.
By Kristin Jensen • May 15, 2024 -
Getty Images
Novo Holdings buys stake in life sciences tools company; BioMarin lays off 170
The parent of Novo Nordisk is acquiring 60% ownership of Single Use Support, which specializes in handling of advanced therapies. Elsewhere, BioMarin and gene therapy developer Tenaya are cutting jobs.
By Ned Pagliarulo • May 15, 2024 -
Permission granted by FogPharma
FogPharma, Artbio join forces to design a different radiopharma drug
The biotechs aim to marry FogPharma’s polypeptide science with Artbio’s lead-based radiopharmaceutical technology in one of the industry’s hottest fields.
By Ned Pagliarulo • May 14, 2024 -
Getty Images
Sands Capital raises $555M fund amid upturn in biotech ‘crossover’ investing
The firm, one of the sector’s more active crossover investors, closed the fund during a surge in the financings that bridge biotechs to the public markets.
By Ben Fidler • May 14, 2024 -
Courtesy of Sanofi
Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
The deal gives the pharma partial rights to a medicine GSK once developed for heart disease but could soon become the first therapy for facioscapulohumeral muscular dystrophy.
By Jonathan Gardner • May 13, 2024 -
Permission granted by Ajax Therapeutics
Ajax, aiming for a better JAK drug, raises $95M to begin first tests
Goldman Sachs and Eli Lilly are among those backing the startup, which claims its prospect could be more potent than the myelofibrosis therapies that have come to market in recent years.
By Gwendolyn Wu • May 13, 2024 -
Getty Images
NewVale, an unorthodox investment firm, sets out to support biotech’s ‘infrastructure’
The firm, which closed a $167 million fund, aims to fill a “crucial gap” by growing the companies startups turn to for outsourced services, founder Todd Holmes told BioPharma Dive.
By Ben Fidler • May 13, 2024 -
Getty Images
iTeos shares jump on TIGIT update; Acelyrin swaps CEOs
Interim data surpassed expectations, iTeos said. Bluebird bio, meanwhile, gave a fuller accounting of launch progress for its gene therapies Lygenia, Zynteglo and Skysona.
By BioPharma Dive staff • May 10, 2024 -
Permission granted by Maze Therapeutics
Maze lands new partner for Pompe drug, after Sanofi pact came apart
An alliance with Shionogi involves similar terms as a deal Sanofi canceled in response to an unusual challenge from the Federal Trade Commission.
By Ben Fidler • May 10, 2024 -
Courtesy of Novo Nordisk
Novo taps another Flagship startup in search for next obesity drugs
The deal with Metaphore Biotechnologies is the third from a Flagship alliance meant to boost the Danish drugmaker’s pipeline of weight loss medicines.
By Gwendolyn Wu • May 9, 2024 -
Seth Babin/BioPharma Dive
Verve moves forward with backup base editing therapy
Weeks after a safety setback derailed its lead candidate, the company has treated the first participant in a trial of its heart disease treatment Verve-102.
By Ned Pagliarulo • May 7, 2024 -
Getty Images
Zenas, with new funding, aims dual-targeting antibody at lupus and MS
The $200 million round is the latest evidence that surging interest in autoimmune disease cell therapies could expand to include developers of bispecific antibodies.
By Ben Fidler • May 7, 2024 -
Permission granted by Prologue Medicines
Prologue, Flagship’s newest startup, looks to mine viruses for new drugs
The company is using what it claims is the largest database of viral protein structures to unearth medicines for a range of diseases, said CEO and Flagship origination partner Lovisa Afzelius.
By Gwendolyn Wu • May 7, 2024 -
Permission granted by Bluebird bio
Bluebird, Vertex prep for first commercial use of sickle cell gene therapies
One patient has started the treatment process for Bluebird's Lyfgenia, while five others have done the same for Vertex's Casgevy.
By Ned Pagliarulo • Updated May 7, 2024 -
Permission granted by Qiagen
Sponsored by QiagenFree pathway analysis: How much do you really save?
Can free bioinformatics tools get the job done?
May 6, 2024 -
Permission granted by Nasdaq, Inc.
CG follows big IPO with new results for bladder cancer drug
Newly disclosed Phase 3 results presented Friday match findings the biotech disclosed last year, while offering a more comprehensive look at how its drug stacks up to rival therapies.
By Gwendolyn Wu • May 3, 2024
Previous
